Drug intelligence / Profile preview

insuman comb 25

Development stage
Phase 3
Lead developer
Sanofi
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Insuman Comb 25 is a pre-mixed, biphasic human insulin formulation used to manage blood glucose in both type 1 and type 2 diabetes mellitus in adults and children. It contains 25% soluble (short-acting) human insulin and 75% isophane (intermediate-acting) human insulin in suspension. This drug replaces or supplements endogenous insulin, facilitating glucose uptake in muscle and fat tissues and inhibiting hepatic glucose production, thereby lowering blood sugar levels following meals and maintaining glycemic control. It is produced by recombinant DNA technology and is intended for subcutaneous administration. Insuman Comb 25 reduces the risk of microvascular and macrovascular diabetes complications, including retinopathy, nephropathy, and neuropathy.

Brand names
Insuman Comb 25
Other names
human insulin isophane/soluble human insulin 25/75biphasic isophane insulininsuman 25 comb penfillinsuman25 comb penfillinsuman-25 comb penfill
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insuman comb 25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insuman comb 25.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call